Psychedelic DMT trial aims to curb alcohol addiction

NCT ID NCT06070649

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests whether the psychedelic drug DMT, combined with psychotherapy, can help people with alcohol use disorder. 63 participants will receive either a moderate or low dose of DMT, or a placebo, and their safety and desire to drink will be measured. The goal is to see if the psychedelic experience can reduce alcohol consumption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DMT (dimethyltryptamine), a psychedelic drug
What this could lead to: If it works, this could point toward a new treatment option for alcohol use disorder that combines a psychedelic experience with therapy.
What could go wrong: This is a very early Phase 1 trial with only 63 people, focused on safety. It is too soon to know if DMT actually helps reduce drinking, and psychedelics can cause intense psychological reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Alcohol Drinking alcohol-related disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE ALCOHOL USE DISORDER (AUD) ALCOHOL-RELATED DISORDERS

Contacts and locations

Locations

Connecticut Mental Health Center
RECRUITING

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.